相关实验视频
Updated: Jan 30, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
对于性结肠炎的二线因弗利西马布治疗 (SLIT-UC):一项回顾性队列研究
Ciarán P C Galts1, Sama Anvari2, Mawiyah Haq2
1Department of Medicine (Division of Gastroenterology), McMaster University.
性结肠炎的治疗方法Infliximab是有效的,但在其他先进疗法后使用时,响应率较低. 剂量升级也更常见于二线使用因弗利西马布 (infliximab) 的情况.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在先进治疗失败后,因弗利西马布作为二线治疗性结肠炎 (UC) 的有效性尚未得到充分证实.
- 尽管注册试验数据有限,但Infliximab在这个序列中越来越多地被使用.
- 本研究评估了二线infliximab的有效性,并将其与一线使用进行比较.
研究的目的:
- 评估Infliximab作为中度至重度性结肠炎的二线治疗的有效性.
- 在接受二线因弗利克西马布的患者中确定临床缓解的预测因素.
- 为了比较UC的第一线与二线infliximab治疗的结果.
主要方法:
- 对225名成年UC患者进行了回顾性队列研究,这些患者接受了infliximab治疗.
- 患者分为一线和二线 (或后续) 治疗组.
- 对比1年的临床和内镜结果;用于确定缓解预测因子的多变量逻辑回归.
主要成果:
- 二线因弗利西马布的使用与显著较低的1年临床反应相关 (OR0.53,P=0.049).
- 剂量升级在二线使用者中更频繁 (57.3%对42.0%,P=0.026).
- 在二线使用者中观察到数量较低,但在统计学上不显著的内镜和组织学缓解率.
结论:
- 性结肠炎的二线药物Infliximab仍然有效.
- 减少的应答率和增加的剂量升级需要优化患者选择二线治疗.
- 对于暴露于治疗的UC群体需要进一步的策略.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Gene Therapy